PharmaCyte Biotech, Inc.
PMCBNASDAQHealthcare● Active
$0.70
+$0.00(+0.00%)
Market Cap$4757046
P/E Ratio—
52W High$1.51
52W Low$0.63
PharmaCyte Biotech, Inc.（PMCB）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PMCB · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-04 | 2024-04 | 2023-04 | 2022-04 | 2021-04 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.03B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.03B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.46 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.02B | 0.02B | 0.00B |
| EBITDA | $0.03B | $0.01B | ($0.00B) | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解PharmaCyte Biotech, Inc.
关于PharmaCyte Biotech, Inc.（PMCB）损益表
PharmaCyte Biotech, Inc.（PMCB）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，PMCB实现营收$0.00B，毛利润$0.00B（毛利率—），净利润$0.03B（净利率—）。
常见问题
PMCB · 4 问PharmaCyte Biotech, Inc.（PMCB）2025财年营收为$0.00B，同比down—%。
PMCB revenuePMCB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08